Cellular hierarchy framework based on single-cell and bulk RNA sequencing reveals fatty acid metabolic biomarker MYDGF as a therapeutic target for ccRCC

BackgroundFatty acid metabolism (FAM) reprogramming is a prominent feature of clear cell renal cell carcinoma (ccRCC). Nevertheless, the effect of FAM reprogramming on the heterogeneity and prognosis of ccRCC individuals remains insufficiently understood.MethodsWe utilized single-cell sequencing and...

Full description

Saved in:
Bibliographic Details
Main Authors: Ning Wang, Ziyu Xu, Lina Zhang, Yanfang Lu, Yanliang Wang, Lei Yan, Huixia Cao, Limeng Wang, Fengmin Shao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1615601/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850233536244613120
author Ning Wang
Ziyu Xu
Lina Zhang
Lina Zhang
Yanfang Lu
Yanfang Lu
Yanliang Wang
Yanliang Wang
Lei Yan
Lei Yan
Huixia Cao
Huixia Cao
Limeng Wang
Limeng Wang
Fengmin Shao
Fengmin Shao
author_facet Ning Wang
Ziyu Xu
Lina Zhang
Lina Zhang
Yanfang Lu
Yanfang Lu
Yanliang Wang
Yanliang Wang
Lei Yan
Lei Yan
Huixia Cao
Huixia Cao
Limeng Wang
Limeng Wang
Fengmin Shao
Fengmin Shao
author_sort Ning Wang
collection DOAJ
description BackgroundFatty acid metabolism (FAM) reprogramming is a prominent feature of clear cell renal cell carcinoma (ccRCC). Nevertheless, the effect of FAM reprogramming on the heterogeneity and prognosis of ccRCC individuals remains insufficiently understood.MethodsWe utilized single-cell sequencing and spatial transcriptomics to investigate the heterogeneity of FAM in ccRCC comprehensively. Functional enrichment algorithms, including AUCell, UCell, singscore, ssGSEA, and AddModuleScore, along with hdWGCNA analysis, were used to identify hub genes influencing high FAM of ccRCC. Machine learning methods were then applied to pinpoint the optimal feature gene. The function of the selected genes in FAM was validated through clinical samples and cellular functional experiments.ResultsThe results revealed significant upregulation of FAM in malignant epithelial cells. Through five distinct enrichment scoring methods and hdWGCNA analysis, we redefined a gene set related to increased FAM at the single-cell level. By the integration of this gene set with bulk transcriptomic data and the application of machine-learning algorithms, we found four candidate genes—MYDGF, ZNHIT1, HMGN3, and ARL6IP4—that were linked to ccRCC progression. Bulk RNA sequencing validated their increased expression in ccRCC individuals, underscoring their diagnostic and prognostic potential. Single-cell analysis further revealed that these genes were primarily upregulated in malignant epithelial cells, emphasizing their cell-specific roles in ccRCC. It was verified that MYDGF could promote cell proliferation, migration and invasion while inhibiting cell apoptosis. Functional experiments further confirmed that MYDGF is a key FAM-related biomarker that enhances lipid deposition by suppressing fatty acid oxidation, thereby accelerating tumor progression.ConclusionsMYDGF was identified as a FAM-related oncogenic biomarker that promotes ccRCC progression by inhibiting fatty acid oxidation. Our findings elucidated the cellular hierarchy of ccRCC from the perspective of FAM reprogramming and may offer new insights and therapeutic targets for future ccRCC treatments.
format Article
id doaj-art-618b9b07ff9745e6bb367764b3fc1a41
institution OA Journals
issn 1664-3224
language English
publishDate 2025-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-618b9b07ff9745e6bb367764b3fc1a412025-08-20T02:02:54ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-06-011610.3389/fimmu.2025.16156011615601Cellular hierarchy framework based on single-cell and bulk RNA sequencing reveals fatty acid metabolic biomarker MYDGF as a therapeutic target for ccRCCNing Wang0Ziyu Xu1Lina Zhang2Lina Zhang3Yanfang Lu4Yanfang Lu5Yanliang Wang6Yanliang Wang7Lei Yan8Lei Yan9Huixia Cao10Huixia Cao11Limeng Wang12Limeng Wang13Fengmin Shao14Fengmin Shao15Department of Nephrology, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Nephrology, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Nephrology, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaHenan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Nephrology, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaHenan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Nephrology, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaHenan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Nephrology, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaHenan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Nephrology, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaHenan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Nephrology, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaHenan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Nephrology, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaHenan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial Clinical Research Center for Kidney Disease, Henan Provincial People’s Hospital, Zhengzhou, ChinaBackgroundFatty acid metabolism (FAM) reprogramming is a prominent feature of clear cell renal cell carcinoma (ccRCC). Nevertheless, the effect of FAM reprogramming on the heterogeneity and prognosis of ccRCC individuals remains insufficiently understood.MethodsWe utilized single-cell sequencing and spatial transcriptomics to investigate the heterogeneity of FAM in ccRCC comprehensively. Functional enrichment algorithms, including AUCell, UCell, singscore, ssGSEA, and AddModuleScore, along with hdWGCNA analysis, were used to identify hub genes influencing high FAM of ccRCC. Machine learning methods were then applied to pinpoint the optimal feature gene. The function of the selected genes in FAM was validated through clinical samples and cellular functional experiments.ResultsThe results revealed significant upregulation of FAM in malignant epithelial cells. Through five distinct enrichment scoring methods and hdWGCNA analysis, we redefined a gene set related to increased FAM at the single-cell level. By the integration of this gene set with bulk transcriptomic data and the application of machine-learning algorithms, we found four candidate genes—MYDGF, ZNHIT1, HMGN3, and ARL6IP4—that were linked to ccRCC progression. Bulk RNA sequencing validated their increased expression in ccRCC individuals, underscoring their diagnostic and prognostic potential. Single-cell analysis further revealed that these genes were primarily upregulated in malignant epithelial cells, emphasizing their cell-specific roles in ccRCC. It was verified that MYDGF could promote cell proliferation, migration and invasion while inhibiting cell apoptosis. Functional experiments further confirmed that MYDGF is a key FAM-related biomarker that enhances lipid deposition by suppressing fatty acid oxidation, thereby accelerating tumor progression.ConclusionsMYDGF was identified as a FAM-related oncogenic biomarker that promotes ccRCC progression by inhibiting fatty acid oxidation. Our findings elucidated the cellular hierarchy of ccRCC from the perspective of FAM reprogramming and may offer new insights and therapeutic targets for future ccRCC treatments.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1615601/fullfatty acid metabolismccRCCMYDGFScRNA-seqmachine learning
spellingShingle Ning Wang
Ziyu Xu
Lina Zhang
Lina Zhang
Yanfang Lu
Yanfang Lu
Yanliang Wang
Yanliang Wang
Lei Yan
Lei Yan
Huixia Cao
Huixia Cao
Limeng Wang
Limeng Wang
Fengmin Shao
Fengmin Shao
Cellular hierarchy framework based on single-cell and bulk RNA sequencing reveals fatty acid metabolic biomarker MYDGF as a therapeutic target for ccRCC
Frontiers in Immunology
fatty acid metabolism
ccRCC
MYDGF
ScRNA-seq
machine learning
title Cellular hierarchy framework based on single-cell and bulk RNA sequencing reveals fatty acid metabolic biomarker MYDGF as a therapeutic target for ccRCC
title_full Cellular hierarchy framework based on single-cell and bulk RNA sequencing reveals fatty acid metabolic biomarker MYDGF as a therapeutic target for ccRCC
title_fullStr Cellular hierarchy framework based on single-cell and bulk RNA sequencing reveals fatty acid metabolic biomarker MYDGF as a therapeutic target for ccRCC
title_full_unstemmed Cellular hierarchy framework based on single-cell and bulk RNA sequencing reveals fatty acid metabolic biomarker MYDGF as a therapeutic target for ccRCC
title_short Cellular hierarchy framework based on single-cell and bulk RNA sequencing reveals fatty acid metabolic biomarker MYDGF as a therapeutic target for ccRCC
title_sort cellular hierarchy framework based on single cell and bulk rna sequencing reveals fatty acid metabolic biomarker mydgf as a therapeutic target for ccrcc
topic fatty acid metabolism
ccRCC
MYDGF
ScRNA-seq
machine learning
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1615601/full
work_keys_str_mv AT ningwang cellularhierarchyframeworkbasedonsinglecellandbulkrnasequencingrevealsfattyacidmetabolicbiomarkermydgfasatherapeutictargetforccrcc
AT ziyuxu cellularhierarchyframeworkbasedonsinglecellandbulkrnasequencingrevealsfattyacidmetabolicbiomarkermydgfasatherapeutictargetforccrcc
AT linazhang cellularhierarchyframeworkbasedonsinglecellandbulkrnasequencingrevealsfattyacidmetabolicbiomarkermydgfasatherapeutictargetforccrcc
AT linazhang cellularhierarchyframeworkbasedonsinglecellandbulkrnasequencingrevealsfattyacidmetabolicbiomarkermydgfasatherapeutictargetforccrcc
AT yanfanglu cellularhierarchyframeworkbasedonsinglecellandbulkrnasequencingrevealsfattyacidmetabolicbiomarkermydgfasatherapeutictargetforccrcc
AT yanfanglu cellularhierarchyframeworkbasedonsinglecellandbulkrnasequencingrevealsfattyacidmetabolicbiomarkermydgfasatherapeutictargetforccrcc
AT yanliangwang cellularhierarchyframeworkbasedonsinglecellandbulkrnasequencingrevealsfattyacidmetabolicbiomarkermydgfasatherapeutictargetforccrcc
AT yanliangwang cellularhierarchyframeworkbasedonsinglecellandbulkrnasequencingrevealsfattyacidmetabolicbiomarkermydgfasatherapeutictargetforccrcc
AT leiyan cellularhierarchyframeworkbasedonsinglecellandbulkrnasequencingrevealsfattyacidmetabolicbiomarkermydgfasatherapeutictargetforccrcc
AT leiyan cellularhierarchyframeworkbasedonsinglecellandbulkrnasequencingrevealsfattyacidmetabolicbiomarkermydgfasatherapeutictargetforccrcc
AT huixiacao cellularhierarchyframeworkbasedonsinglecellandbulkrnasequencingrevealsfattyacidmetabolicbiomarkermydgfasatherapeutictargetforccrcc
AT huixiacao cellularhierarchyframeworkbasedonsinglecellandbulkrnasequencingrevealsfattyacidmetabolicbiomarkermydgfasatherapeutictargetforccrcc
AT limengwang cellularhierarchyframeworkbasedonsinglecellandbulkrnasequencingrevealsfattyacidmetabolicbiomarkermydgfasatherapeutictargetforccrcc
AT limengwang cellularhierarchyframeworkbasedonsinglecellandbulkrnasequencingrevealsfattyacidmetabolicbiomarkermydgfasatherapeutictargetforccrcc
AT fengminshao cellularhierarchyframeworkbasedonsinglecellandbulkrnasequencingrevealsfattyacidmetabolicbiomarkermydgfasatherapeutictargetforccrcc
AT fengminshao cellularhierarchyframeworkbasedonsinglecellandbulkrnasequencingrevealsfattyacidmetabolicbiomarkermydgfasatherapeutictargetforccrcc